Table 2.
Treatment and response by mutation.
|
All (n = 37) |
Tissue | Blood | |||||
|---|---|---|---|---|---|---|---|
|
T790M neg (n = 7) |
T790M pos (n = 8) |
Unknown (n = 22) |
T790M neg (n = 17) |
T790M pos (n = 12) |
Unknown (n = 8) |
||
| Total cycles, median (range) | 4 (1–15) | 4 (2–6) | 3 (2–15) | 3.5 (1–14) | 6 (2–15) | 2 (1–6) | 3 (2–14) |
| Off Treatment Reason, n (%) | |||||||
| Progression | 33 (89.2) | 6 (85.7) | 7 (87.5) | 20 (90.9) | 14 (82.3) | 12 (100.0) | 7 (87.5) |
| Toxicity | 2 (5.4) | 1 (14.3) | 0 | 1 (4.5) | 1 (5.9) | 0 (0.0) | 1 (12.5) |
| Other | 2 (5.4) | 0 | 1 (12.5) | 1 (4.5) | 2 (11/8) | 0 (0.0) | 0 (0.0) |
| Best Overall Response, n (%) | |||||||
| Partial response | 4 (10.8%) | 0 | 1 (12.5) | 3 (13.6%) | 3 (17.7) | 0 (0.0%) | 1 (12.5) |
| Progressive disease | 12 (32.4) | 1 (14.3) | 4 (50) | 7 (31.8) | 2 (11.8) | 7 (58.3) | 3 (37.5) |
| ORR (95%CI) | 10.8% (0.3, 21.3) | 0% | 12.5% (0, 42.1) |
13.6% (0, 29.2) | 17.6% (0, 37.8) |
0 | 12.5% (0, 42.1) |
| DCR at 8 weeks (95%CI) | 67.6% (51.7, 83.4) |
85.7% (50.8,100) | 50.0% (5.3, 94.7) |
68.2% (47.0, 89.3) |
88.2% (71.1, 100) |
41.7% (8.9, 74.4) |
62.5% (19.2, 100) |
| Follow-up (mo), median (range) | 11.0 (1.6, 26.6) | 8.6 (2.4, 16.0) | 13.1 (2.8, 20.1) | 11.1 (1.6, 26.6) | 12.7 (2.4, 21.2) | 9.2 (2.1, 17.4) | 10.3 (1.6, 26.6) |